SEC
AMLX icon

Seven Eight Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Seven Eight Capital’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-66,801
Closed -$983K – 598
2023
Q4 		$983K Buy
66,801
+6,910
+12% +$106K 0.11% 256
2023
Q3 		$1.1M Buy
+59,891
New +$1.27M 0.13% 223
2023
Q2 		– Sell
-30,053
Closed -$882K – 485
2023
Q1 		$882K Buy
30,053
+15,115
+101% +$525K 0.18% 153
2022
Q4 		$552K Buy
14,938
+2,876
+24% +$102K 0.14% 211
2022
Q3 		$340K Buy
+12,062
New +$301K 0.07% 351

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Seven Eight Capital's AMLX Position: Q1 2024 in Review

Seven Eight Capital sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2024, closing a stake of 66,801 shares — an estimated $983K sold.

Seven Eight Capital first reported a position in AMLX in Q3 2022 and held it in 5 quarters. The position peaked at $1.1M in Q3 2023. 143 funds tracked by Wall St. Rank hold AMLX as of Q1 2024.

  • Seven Eight Capital reported no remaining Amylyx Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Seven Eight Capital sold 66,801 Amylyx Pharmaceuticals shares in Q1 2024, an estimated $983K.
  • Seven Eight Capital first reported a position in Amylyx Pharmaceuticals in Q3 2022 and held it in 5 quarters.
  • Seven Eight Capital's Amylyx Pharmaceuticals position peaked at $1.1M in Q3 2023.
  • 143 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2024.

Based on Seven Eight Capital's 13F filing for Q1 2024, filed 13 May 2024.